Elanco director buys 40,000 shares at $23.40

Elanco Animal Health Inc (ELAN) director Lawrence Erik Kurzius reported an open-market purchase of 40,000 shares of common stock on August 20, 2026 at a weighted average price of $23.398 per share, with individual trades ranging from $23.385 to $23.40.

Rhea-AI Filing Summary

Elanco Animal Health Inc (ELAN) director Lawrence Erik Kurzius reported an open-market purchase of 40,000 shares of common stock on August 20, 2026 at a weighted average price of $23.398 per share, with individual trades ranging from $23.385 to $23.40. Following these purchases, his reported direct holdings increased to 188,647 shares of Elanco common stock.

Insider Trade Summary

Net Buyer: 40,000 shares

Net Buy 1 txn

Insider Kurzius Lawrence Erik

Role Director

Bought 40,000 shs ($936K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	40,000	$23.398	$936K

Holdings After Transaction: Common Stock — 188,647 shares (Direct)

Footnotes (1)

1. F1. Reflects the weighted average price of 40,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on August 20, 2026 with purchase prices ranging from $23.385 to $23.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Key Figures

Shares purchased: 40,000 shares Weighted average purchase price: $23.398 per share Purchase price range: $23.385–$23.40 per share +1 more

4 metrics

Shares purchased 40,000 shares Common stock acquired on August 20, 2026

Weighted average purchase price $23.398 per share Average price for 40,000 ELAN shares bought on August 20, 2026

Purchase price range $23.385–$23.40 per share Range of individual transaction prices on August 20, 2026

Shares owned after transaction 188,647 shares Direct holdings of ELAN common stock following the reported purchase

Key Terms

Form 4, weighted average price, open market

3 terms

Form 4 regulatory

"reported in a Form 4 insider transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

weighted average price financial

"Reflects the weighted average price of 40,000 shares"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"Purchase in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ELAN director Lawrence Erik Kurzius report?

He reported purchasing 40,000 shares of Elanco Animal Health Inc common stock on August 20, 2026 in open-market transactions, at a weighted average price of $23.398 per share, with individual purchase prices between $23.385 and $23.40 per share.

At what price did the ELAN shares trade in the reported insider purchase?

The reported weighted average purchase price was $23.398 per ELAN share. According to the disclosure, the 40,000 shares were bought in multiple trades on August 20, 2026, with individual transaction prices ranging from $23.385 to $23.40 per share.

How many ELAN shares does Lawrence Erik Kurzius hold after this Form 4 transaction?

After the reported purchases, Lawrence Erik Kurzius directly holds 188,647 shares of Elanco Animal Health Inc common stock, as disclosed in the Form 4 filing covering the August 20, 2026 transactions.

Was the ELAN insider trade by Lawrence Erik Kurzius a purchase or a sale?

The reported transaction was a purchase. The Form 4 indicates code "P" (purchase in open market or private transaction) and shows that 40,000 shares of Elanco common stock were acquired by Lawrence Erik Kurzius on August 20, 2026.

How many ELAN shares did Lawrence Erik Kurzius buy in the latest Form 4?

He bought 40,000 shares of Elanco Animal Health Inc common stock. The Form 4 states that these shares were acquired in multiple open-market transactions on August 20, 2026, with a weighted average price of $23.398 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:17 PM Accepted by SEC EDGAR 08/21/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kurzius Lawrence Erik

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS INDIANA 46221

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2026		P		40,000	A	$23.398(1)	188,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the weighted average price of 40,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on August 20, 2026 with purchase prices ranging from $23.385 to $23.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Lawrence Kurzius	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)